Revisiting Immune Checkpoints in Medulloblastoma
Description
This presentation will discuss the immune landscape of medulloblastoma including immune checkpoint expression and translational relevance.
Neuro-oncology: Immunotherapy for Glioblastoma*
Date: September 15, 2025
Time: 4:15 pm to 5:45 pm
Track: Traditional Special Interest Group (SIG)
Session Description
In the past decade, there has been a proliferation of clinical and translational studies using immunomodulatory agents or cells against adult glioblastoma, a deadly malignancy in the brain. Although initial trials using off-the-shelve checkpoint inhibitors did not improve progression-free survival or overall survival in this population, newer strategies like patient derived personalized cellular immunotherapy, neoantigen peptide vaccine, and CAR-T therapy show promise. In this session, we will review some of these advanced immunotherapy strategies for glioblastoma.
Learning Objectives
At the conclusion of the session, attendees should be able to:
- Discuss the various types of cell- and vaccine-based immunotherapies against glioblastoma.
- Discuss potential resistance mechanisms that attenuate anti-glioblastoma immune response.
- Assess the risks and benefits of various types of cell- and vaccine-based immunotherapies for glioblastoma.
Speakers
Reprogramming the Glioblastoma Microenvironment: From Immune Suppression to Immune Activation
Description
This presentation will discuss immunotherapy for glioblastoma, including the role of precision medicine.
Speakers
STING: A Pathway Forward for Immunotherapy in Gliomas
Description
This presentation will provide an overview of STING pathway in the treatment of high-grade gliomas, including ongoing studies and future directions.